GlassScriptPhysician profile
Jerry Dang
NPI 1831826692
$8,462.67
in general payments reported to CMS, 2019-2025
18 companies · $1,603 in 2025
The $1,603 reported for 2025 was more than what 79% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $762 · 2023: $1,653 · 2024: $4,445 · 2025: $1,603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,866 · Travel and Lodging: $1,326 · Consulting Fee: $500 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,865.68 |
| Travel and Lodging | $1,326.16 |
| Consulting Fee | $500.00 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,228.65 | 2022-2025 | Da Vinci Surgical System |
| Medtronic, INC. | $1,643.32 | 2022-2025 | Signia, Endo Gia Ultra, Endoflip |
| W. L. Gore & Associates, INC. | $1,235.68 | 2022-2025 | Gore Enform Preperitoneal Biomaterial, Gore Seamguard Bioabsorbable Staple Line Reinforce |
| Boston Scientific Corporation | $681.79 | 2022-2025 | Spyglass Discover, Spyglass |
| Momentis Surgical INC. | $500.00 | 2024 | Anova Surgical System |
| Stryker Corporation | $235.63 | 2023-2024 | Spy-Phi System, 1788 |
| Ambu INC. | $160.82 | 2024 | |
| Enterra Medical, INC. | $151.35 | 2025 | |
| Teleflex LLC | $132.54 | 2023 | |
| Reshape Lifesciences INC. | $121.38 | 2023 | |
| Endogastric Solutions, INC | $117.72 | 2023 | Esophyx |
| Dilon Technologies, INC. | $85.64 | 2023 | Hemoblast Bellows |
| Baxter Healthcare | $47.60 | 2025 | Tisseel |
| Conmed Corporation | $36.54 | 2024-2025 | Airseal |
| Madrigal Pharmaceuticals | $35.65 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $17.00 | 2024 | |
| Aimmune Therapeutics, INC. | $16.73 | 2025 | Zenpep |
| Davol INC. | $14.63 | 2025 | Phasix Mesh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Dang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.